Presentation:
The Antibody Mediated Prevention (AMP) trials did not demonstrate HIV prevention efficacy (PE) of the CD4-binding-site-targetting broadly neutralizing antibody (bnAb), VRC01 (10mg/kg or 30mg/kg IV vs. placebo). However, 75% PE was observed against viruses sensitive to VRC01 with an IC80 <1 mcg/mL, which constituted 30% of acquired viruses in placebo recipients. In addition, predicted neutralization ID80 (PT80) titer >200 at the estimated time of exposure to a given exposing virus was associated with high PE, validating in humans consistent patterns observed in non-human primate (NHP) challenge studies of different single bnAbs. This knowledge can be applied to predict PE of combinations of long-acting LS-modified bnAbs targeting non-overlapping HIV epitopes. As with combination anti-retroviral-therapy for HIV treatment, combination bnAbs may overcome neutralization resistance and provide more potent coverage for HIV prevention.